GLPwatch
Papers (12034)
Page 60 of 201, ranked by citation count.
- Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
- Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study.
- Exenatide-induced chronic damage of pancreatic tissue in rats.
- Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
- Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models.
- Microglial Activation of GLP-1R Signaling in Neuropathic Pain Promotes Gene Expression Adaption Involved in Inflammatory Responses.
- Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.
- Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development.
- Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
- Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro.
- Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
- Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
- Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
- Once weekly exenatide: efficacy, tolerability and place in therapy.
- Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.
- Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
- Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.
- Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
- A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies.
- Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.
- Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.
- Long-term functional alterations following prenatal GLP-1R activation.
- Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model.
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
- A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation <i>via</i> Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine.
- Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.
- Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models.
- Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
- Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
- Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis.
- A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD<sub>2</sub>-microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus.
- Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
- Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy.
- Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
- Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice.
- Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.
- Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials.
- Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
- The Effects of pH and Excipients on Exenatide Stability in Solution.
- Semaglutide in Cystic Fibrosis-Related Diabetes.
- The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.
- A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up.
- Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
- Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.
- PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
- Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro.
- Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.
- Eosinophil-rich granulomatous panniculitis caused by exenatide injection.
- Liraglutide, a glucagon-like peptide-1 analog, inhibits high glucose-induced oxidative stress and apoptosis in neonatal rat cardiomyocytes.
- Liraglutide Inhibits Osteoclastogenesis and Improves Bone Loss by Downregulating Trem2 in Female Type 1 Diabetic Mice: Findings From Transcriptomics.
- Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.
- GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.
- Tf ligand-receptor-mediated exenatide-Zn<sup>2+</sup> complex oral-delivery system for penetration enhancement of exenatide.
- Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
- LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet.
- Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
- Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
- Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.
- Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes.